Evaluation of melanocytic neoplasms: Application of a pan-melanoma antibody cocktail

British Journal of Biomedical Science

Volumn 59, Issue 4, 2002, Pages 196-202

  Orchard, Guy ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Immunohistochemistry; Melanoma

Indexed keywords

CANCER ANTIBODY; MELAN A; MELANOMA ANTIBODY; MONOCLONAL ANTIBODY HMB 45; MONOPHENOL MONOOXYGENASE; POLYCLONAL ANTIBODY; PROTEIN S 100; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; TUMOR MARKER;

ANTIBODY LABELING; ARTICLE; BASAL CELL CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; MELANOMA CELL; NEVUS; PRIORITY JOURNAL; SKIN METASTASIS; SQUAMOUS CELL CARCINOMA; DIFFERENTIAL DIAGNOSIS; ENZYME IMMUNOASSAY; EVALUATION; IMMUNOLOGY; LYMPH NODE METASTASIS; METASTASIS; PIGMENTED NEVUS; SKIN TUMOR;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MELANOMA; NEVUS, PIGMENTED; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0038814094     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2002.11783659     Document Type: Article

References (17)

1. 1 Marks R. Epidemiology of melanoma. Clin Dermatol 2000; 25: 459-63.
2. Rigel DS. The gender-related issues in malignant melanoma. Hawaii Med J 1993; 52: 124-46.
3. Zelger BG, Steiner H, Wambacher B et al. Malignant melanoma simulating various types of soft tissue tumors. Dermatol Surg 1997; 23: 1047-53.
4. Orchard GE. Comparison of immunohistochemical labelling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma. Histochem J 2000; 32: 475-81.
5. Russell Jones R, Acland K. Sentinel node biopsy in the management of malignant melanoma. Clin Dermatol 2001; 26: 463-8.
6. Biocarta Europe. Pan-melanoma cocktail data sheet.
7. Orchard GE, Wilson Jones E. Immunocytochemistry in the diagnosis of malignant melanoma. Br J Biomed Sci 1994; 51: 44-56.
8. de Vries T, Smeets M, de Graaf R et al. Expression of gp100, MART-1, tyrosinase and S100 in paraffin-embedded primary melanomas and locoregional lymph node and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group. J Pathol 2001; 193: 13-20.
9. Hochberg M, Lotem M, Gimon Z et al. Expression of tyrosinase, MIA and MART-1 in sentinel lymph nodes of patients with malignant melanoma. Br J Dermatol 2001; 146: 244-9.
10. Achilles E, Schroder S. Positive cytokeratin results in malignant melanoma. Pitfall in differential immunohistological diagnosis of occult neoplasms. Pathologe 1994; 15: 235-41.
11. Pea M, Bonetti F, Zamboni G et al. Melanocyte marker HMB 45 is regularly expressed in anglomyolipoma of the kidney. Pathology 1991; 23: 185-8.
12. Anstey A, Cerio R, Ramnarain R et al. Desmoplastic malignant melanoma. An immunocytochemical study of 25 cases. Am J Dermatopathol 1994; 16: 14-22.
13. Magennis DP, Orchard GE. Malignant melanoma, death by image and ignorance, diagnosis by surgical excision and laboratory investigation. Br J Biomed Sci 1999; 56: 134-44.
14. King R, Googe PB, Weilbaecher KN et al. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic and nonmelanocytic tumors. Am J Surg Pathol 2001; 25: 51-7.
15. Granter SR, Weilbaecher KN, Quigley C et al. Microphthalmia transcription factor. Not a sensitive or specific marker for the diagnosis of desmoplastic melanoma and spindle cell (non-desmoplastic) melanoma. Am J Dermatopathol 2001; 23: 185-9.
16. Koch MB, Shih IM, Weiss S et al. Microphthalmia transcription factor and melanoma cell adhesion molecule expression distinguish desmoplastic/spindle cell melanoma from morphologic mimics. Am J Surg-Pathol 2001; 25: 58-64.
17. Hoang MP, Selim MA, Bentley RC. CD34 expression in desmoplastic melanoma. J Cutan Pathol 2001; 20: 508-12.